• menu

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Trusted Global CDMO Partner Delivering End-to-End Pharma Manufacturing & Development Solutions.
    |
    Weekly News Recap #Phispers
    Moderna resolves vaccine patent dispute with Roivant, Arbutus; FDA grants accelerated approval to Ascendis’ dwarfism therapy

    Moderna resolves vaccine patent dispute with Roivant, Arbutus; FDA grants accelerated approval to Ascendis’ dwarfism therapy

    Over the past week, tensions in the Middle East have escalated sharply after the US and Israel launched military strikes on Ira...

    Impressions : 492

    Gilead buys Arcellx for US$ 7.8 billion; FDA approves Vanda’s antipsychotic pill for bipolar disorder, schizophrenia

    Gilead buys Arcellx for US$ 7.8 billion; FDA approves Vanda’s antipsychotic pill for bipolar disorder, schizophrenia

    In this week’s news, Gilead Sciences has entered into an agreement to acquire its cancer therapy partner Arcellx for US$ ...

    Impressions : 635

    FDA agrees to review Moderna’s amended mRNA-based flu vaccine application; Lilly builds orforglipron stock ahead of approval

    FDA agrees to review Moderna’s amended mRNA-based flu vaccine application; Lilly builds orforglipron stock ahead of approval

    Last week, the US Food and Drug Administration (FDA) had said it will not review Moderna’s application for its experiment...

    Impressions : 1518

    FDA refuses to review Moderna’s mRNA-based flu vaccine application; Lilly buys Orna for up to US$ 2.4 billion

    FDA refuses to review Moderna’s mRNA-based flu vaccine application; Lilly buys Orna for up to US$ 2.4 billion

    The US Food and Drug Administration (FDA) has said it will not review Moderna’s application for its experimental influenz...

    Impressions : 1526

    Lilly expects 25% growth, Novo sees its sales drop in 2026; Amgen turns down FDA request to withdraw rare disease drug

    Lilly expects 25% growth, Novo sees its sales drop in 2026; Amgen turns down FDA request to withdraw rare disease drug

    In this week’s Phispers, we bring you the split story of two GLP-1 drugmakers — Eli Lilly and Novo Nordisk. While L...

    Impressions : 1124

    US exits WHO; Moderna to stop investing in new late-stage vaccine trials due to increased opposition to immunizations

    US exits WHO; Moderna to stop investing in new late-stage vaccine trials due to increased opposition to immunizations

    Public health suffered several setbacks over the last week. First, the United States formally exited the World Health Organiza...

    Impressions : 1498

    J&J’s 2026 sales may cross US$ 100 bn; FDA delays fast-track reviews of drugs under Trump’s voucher program

    J&J’s 2026 sales may cross US$ 100 bn; FDA delays fast-track reviews of drugs under Trump’s voucher program

    In 2022, Pfizer had crossed US$ 100 billion in revenue owing to its Covid products. While that was a one-off, Johnson & Johnson...

    Impressions : 1312

    AbbVie inks US$ 5.6 bn oncology deal with China’s RemeGen; Astra buys Modella AI to speed up cancer drug research

    AbbVie inks US$ 5.6 bn oncology deal with China’s RemeGen; Astra buys Modella AI to speed up cancer drug research

    This week’s Phispers is packed with news from the ongoing JP Morgan Healthcare Conference (JPM26). Notably, AbbVie said i...

    Impressions : 1249

    Sanofi, Earendil Labs ink up to US$ 2.56 bn AI-driven autoimmune drug deal; CDC revises childhood immunization guidelines

    Sanofi, Earendil Labs ink up to US$ 2.56 bn AI-driven autoimmune drug deal; CDC revises childhood immunization guidelines

    The New Year began with two mid-size deals centered around the use of artificial intelligence (AI) in drug development. Sanofi...

    Impressions : 1050

    BioMarin inks US$ 4.8 billion rare disease deal with Amicus; FDA approves pill version of Novo’s Wegovy

    BioMarin inks US$ 4.8 billion rare disease deal with Amicus; FDA approves pill version of Novo’s Wegovy

    PharmaCompass wishes its readers a very Happy New Year and brings news from the last two weeks in this double-dose edition of...

    Impressions : 1268

    FDA okays GSK’s Exdensur as first biologic, add-on med for severe asthma; issues OAI status to Sun Pharma’s India facility

    FDA okays GSK’s Exdensur as first biologic, add-on med for severe asthma; issues OAI status to Sun Pharma’s India facility

    As the year draws to a close, the US Food and Drug Administration (FDA) appears busy approving drugs at a fast pace. This week...

    Impressions : 1146

    Lilly to invest US$ 6 bn in new API plant in Alabama; Biocon buys remaining stake in Biocon Biologics, makes it 100% subsidiary

    Lilly to invest US$ 6 bn in new API plant in Alabama; Biocon buys remaining stake in Biocon Biologics, makes it 100% subsidiary

    In this week’s Phispers, Eli Lilly announced yet another investment in the US — this time to build its largest API ...

    Impressions : 1273

    Lilly cuts price of Zepbound; leaked memo on child deaths due to Covid vaccines triggers reaction from former FDA chiefs

    Lilly cuts price of Zepbound; leaked memo on child deaths due to Covid vaccines triggers reaction from former FDA chiefs

    In Phispers this week, Eli Lilly reduced prices of its obesity drug Zepbound sold through LillyDirect, aiming to expand access...

    Impressions : 1253

    Lilly becomes first pharma to hit US$ 1 tn valuation; FDA clears Padcev-Keytruda combo for bladder cancer

    Lilly becomes first pharma to hit US$ 1 tn valuation; FDA clears Padcev-Keytruda combo for bladder cancer

    In Phispers this week, Eli Lilly became the first pharmaceutical company to reach a market valuation of US$ 1 trillion, driven ...

    Impressions : 1534

    Merck to buy Cidara for US$ 9.2 bn to strengthen infectious disease portfolio; J&J to acquire Halda for US$ 3.05 bn

    Merck to buy Cidara for US$ 9.2 bn to strengthen infectious disease portfolio; J&J to acquire Halda for US$ 3.05 bn

    In this week’s Phispers, Merck struck a US$ 9.2 billion deal to acquire Cidara Therapeutics to strengthen its infectious-...

    Impressions : 949

    Pfizer seals up to US$ 10 bn deal for Metsera; FDA lifts black box warning on hormone therapies for menopause

    Pfizer seals up to US$ 10 bn deal for Metsera; FDA lifts black box warning on hormone therapies for menopause

    In Phispers this week, Pfizer won its high stakes battle with Novo Nordisk for the obesity-focused biotech Metsera. The deal i...

    Impressions : 1225

    Pfizer, Novo escalate bidding war for obesity-drug developer Metsera; Kimberly-Clark to buy Kenvue for US$ 48.7 bn

    Pfizer, Novo escalate bidding war for obesity-drug developer Metsera; Kimberly-Clark to buy Kenvue for US$ 48.7 bn

    As we return from our one-week break due to the CPhI Worldwide, we find our double-dose Phispers edition to be filled with se...

    Impressions : 1207

    Innovent, Takeda ink up to US$ 11.4 bn oncology deal; FDA clears Novo’s Rybelsus to reduce heart risk in diabetics

    Innovent, Takeda ink up to US$ 11.4 bn oncology deal; FDA clears Novo’s Rybelsus to reduce heart risk in diabetics

    In this week’s Phispers, China’s Innovent Biologics signed one of the largest cross-border biotech deals in Asia. U...

    Impressions : 1318

    Novo targets MASH with up to US$ 5.2bn Akero buy; BMS acquires cell therapy developer Orbital for US$ 1.5 bn

    Novo targets MASH with up to US$ 5.2bn Akero buy; BMS acquires cell therapy developer Orbital for US$ 1.5 bn

    In this week’s Phispers, Novo Nordisk and Bristol Myers Squibb (BMS) struck multi-billion-dollar acquisitions to expand t...

    Impressions : 1004

    Chiesi, Arbor in US$ 2 bn gene therapy deal; Lilly to invest over US$ 1 bn in India; FDA okays Boehringer’s rare lung disease drug

    Chiesi, Arbor in US$ 2 bn gene therapy deal; Lilly to invest over US$ 1 bn in India; FDA okays Boehringer’s rare lung disease drug

    In news this week, Italy’s Chiesi Group announced a deal worth up to US$ 2 billion with US-based Arbor Biotechnologies to...

    Impressions : 3754

    Trump, Pfizer seal deal to offer drug discounts; FDA approves Eli Lilly’s oral breast cancer pill

    Trump, Pfizer seal deal to offer drug discounts; FDA approves Eli Lilly’s oral breast cancer pill

    This week, US President Donald Trump announced a deal with Pfizer to sell medicines through a new federal website, TrumpRx.go...

    Impressions : 1016

    Pfizer buys Metsera for up to US$ 7.3 bn, Roche acquires 89bio; FDA okays injectable version of Merck’s Keytruda

    Pfizer buys Metsera for up to US$ 7.3 bn, Roche acquires 89bio; FDA okays injectable version of Merck’s Keytruda

    In this week’s Phispers, Pfizer announced the acquisition of New York-based biotech Metsera for up to US$ 7.3 billion, ma...

    Impressions : 1668

    Novartis inks US$ 5.7 bn licensing deal with Monte Rosa for immune-related diseases; GSK, Lilly pledge more investments in US

    Novartis inks US$ 5.7 bn licensing deal with Monte Rosa for immune-related diseases; GSK, Lilly pledge more investments in US

    In this week’s news, drugmakers continued to invest heavily in the US in order to avoid tariffs. GSK said it will invest ...

    Impressions : 1209

    Advent to sell generic unit to PE firm GTCR for US$ 4.8 billion; Novo shapes up for obesity race by cutting 9,000 jobs

    Advent to sell generic unit to PE firm GTCR for US$ 4.8 billion; Novo shapes up for obesity race by cutting 9,000 jobs

    In this week’s news, Advent International has agreed to sell the Czech generic drugmaker Zentiva to private equity firm G...

    Impressions : 1026

    Novartis inks US$ 5.2 bn cardiology deal with China’s Argo, US$ 2 bn deal with Arrowhead; FDA okays first GLP-1 generic for weight

    Novartis inks US$ 5.2 bn cardiology deal with China’s Argo, US$ 2 bn deal with Arrowhead; FDA okays first GLP-1 generic for weight

    Novartis signed two deals this week — a US$ 5.2 billion cardiology deal with China’s Argo Biopharmaceuticals, and a...

    Impressions : 1094

    White House sacks CDC director; FDA okays Ionis’ Dawnzera, first RNA-based preventive for hereditary angioedema

    White House sacks CDC director; FDA okays Ionis’ Dawnzera, first RNA-based preventive for hereditary angioedema

    The Trump administration has fired US Centers for Disease Control and Prevention (CDC) Director Susan Monarez, post a policy di...

    Impressions : 1355

    FDA grants accelerated approval to Wegovy for treating MASH; Lilly, Superluminal ink US$1.3 bn AI deal to treat obesity

    FDA grants accelerated approval to Wegovy for treating MASH; Lilly, Superluminal ink US$1.3 bn AI deal to treat obesity

    This week’s Phispers brings you updates on key drug approvals. The US Food and Drug Administration (FDA) has granted acce...

    Impressions : 1856

    FDA grants accelerated nod to Boehringer’s lung cancer med; reinstates ousted CBER chief Vinay Prasad

    FDA grants accelerated nod to Boehringer’s lung cancer med; reinstates ousted CBER chief Vinay Prasad

    The US Food and Drug Administration (FDA) has granted an accelerated approval to Boehringer Ingelheim’s Hernexeos (zonger...

    Impressions : 1746

    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.